0:00
0:42 Introducing Dr. Sebastian Sattui.
1:32 Why this meeting is so important.
3:06 The MANDARA Clinical Trial
3:46 The TAPIR Study
5:07 Honoring Dr. Ronald Falk
6:29 Using renal biopsy info or urinary markers to predict how treatments will go for
renal function.
6:59 Results from the VascStrong Study.
9:21 Presentation on AVOCOPAN.
11:25 Excitement around the new response criteria being developed around ANCA vasculitis.
12:23 Focusing on multi-disciplinary care.
14:29 Joyce Kullman: The International Patient Meeting.
16:47 Translating educational materials into other languages.
17:36 Q: Were there any sessions dealing with treatment for PAN?
20:07 Q: Was there a discussion about revisions to the use and timetable with steroids?
22:06 Q: Could you give some more detail about the MANDARA study?
24:48 Q: What would you suggest so that our doctors and medical providers get the information
that you are sharing today.
27:32 Q: Was there any discussion about the use of artificial intelligence technology in vasculitis
research?
2024 Barcelona Vasculitis Workshop: Research Highlights
Recorded May 2024
More than 900 medical professionals from 50 countries came together in Barcelona last month for the 21st International Vasculitis Workshop. Their purpose was to focus on vasculitis and related disorders.
In this webinar, Sebastian Sattui, MD, MS, Director of the UPMC Vasculitis Center in Pittsburgh, shares some of the notable research news, developments, and promising developments presented at the meeting.
Among the studies he discusses:
· MANDARA Study (benralizumab vs mepolizumab) for EGPA
· New data (real life and post hoc analyses) about the efficacy and tolerance of avacopan in AAV